Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vi...

FDA Drug Recall #D-0096-2017 — Class II — September 16, 2016

Recall Summary

Recall Number D-0096-2017
Classification Class II — Moderate risk
Date Initiated September 16, 2016
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Hospira Inc., A Pfizer Company
Location Lake Forest, IL
Product Type Drugs
Quantity 15 vials

Product Description

Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL Multiple-Dose Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1587-50.

Reason for Recall

Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it to be less than the labeled potency.

Distribution Pattern

Nationwide and Puerto Rico

Lot / Code Information

Lot #: 60295DD, Ep 1DEC2017

Other Recalls from Hospira Inc., A Pfizer Company

Recall # Classification Product Date
D-0980-2017 Class III Argatroban Injection, 250 mg/2.5 mL (100 mg/mL)... Jul 6, 2017
D-0898-2017 Class II Levophed norepinephrine bitartrate, injection, ... May 18, 2017
D-0480-2017 Class II METRONIDazole Injection, USP 500 mg (5 mg/mL) i... Feb 10, 2017
D-0638-2017 Class I Vancomycin Hydrochloride for Injection, USP, 10... Jan 24, 2017
D-0097-2017 Class II Marcaine 0.5% (bupivacaine HCl) injection, USP,... Sep 16, 2016

Frequently Asked Questions

Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.